Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.

A woman suffering with rheumatoid arthritis rubs her hands

In a multicentre, dose-ranging trial, led by Professor Chris Buckley at the Universities of Oxford and Birmingham, and sponsored by the Pharmaceutical company GSK, researchers explored the clinical effects of otilimab to prevent inflammation, tissue damage and pain in people with RA.

The study evaluated the effects of five doses of otilimab (22·5 mg, 45 mg, 90 mg, 135 mg, or 180 mg) versus a placebo. 222 patients with active RA received weekly subcutaneous injections for 5 weeks, which was reduced to every other week for one year.  A range of patient reported outcomes for function and pain were measured. Otilimab treatment led to a rapid reduction in tender and swollen joints but patients also reported very significant improvements in pain scores. 

Professor Buckley, Kennedy Professor of Translational Rheumatology at the Universities of Oxford and Birmingham said: “The assumption has always been that if drugs suppress inflammation, they will also help suppress pain, but this hasn’t always been the case. Now, for the first time we are seeing a biologic therapy, the first in the rheumatoid space, that offers two for the price of one. It's suppressing inflammation, but it's also helping pain, and that’s very important to the patient.”

The trial was novel in that it offered an escape arm for patients receiving the placebo or in whom the drug dose to which they were randomised did not achieve a reduction in their disease activity. “One of the problems with placebo arms is it’s hard to get people to go into the study if they know they might get a dummy drug ,” said Prof. Buckley. “In this trial, if a patient wasn’t seeing improvements after 12 weeks they were automatically transferred to the highest dose of otilimab at 180 mg and we were able to then see the improvements.”

This study helped lay the infrastructure groundwork for the CATALYST Trial, also a collaboration between Oxford and Birmingham, which is measuring the effectiveness of GM- CSF and another anti-inflammatory drug (anti TNF) in the treatment of COVID-19.

The results of the trial have been recently published in The Lancet Rheumatology.

The research was funded by GSK.

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Kennedy Main Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

A more tailored approach to treating psoriatic arthritis

Arthritis Botnar Funding Main

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

Motion-capture to help children walk: Oxford team support new gait laboratory in Ethiopia

Main Orthopaedics and trauma

The Research at Oxford on Analysis of Motion (ROAM) team at the University of Oxford have supported CURE Ethiopia Children’s Hospital to develop and open a brand new gait laboratory, the first of its kind in the country and the only other active gait lab on the African continent outside of South Africa.

Professor Eleanor Stride recognised in New Year’s Honours list 2021

Awards Main

Statutory Professor of Biomaterials is awarded Officer of the Order of the British Empire (OBE) for services to Engineering

Drug may boost vaccine responses in older adults

Kennedy Main

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Kennedy Main Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.